Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Sensei Biotherapeutics, Inc. SNSE
$1.48
-$0.01 (-0.67%)
На 18:03, 12 мая 2023
+305.41%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
46766663.00000000
-
week52high
2.39
-
week52low
1.28
-
Revenue
0
-
P/E TTM
-1
-
Beta
-0.20201300
-
EPS
-1.56000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 10 мар 2022 г. |
| Berenberg | Hold | Buy | 01 июл 2021 г. |
| Oppenheimer | Perform | Outperform | 29 июн 2021 г. |
| Piper Sandler | Overweight | 01 мар 2021 г. | |
| Oppenheimer | Outperform | 01 мар 2021 г. | |
| Oppenheimer | Outperform | Perform | 03 окт 2022 г. |
| Citigroup | Buy | 13 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Peyer James | A | 14550 | 14550 | 10 июн 2022 г. |
| Peyer James | A | 5235956 | 4466 | 10 июн 2022 г. |
| Peyer James | A | 5235954 | 4466 | 10 июн 2022 г. |
| Cambrian BioPharma Inc | A | 14550 | 14550 | 10 июн 2022 г. |
| Cambrian BioPharma Inc | A | 5235954 | 4466 | 10 июн 2022 г. |
| Holmen Bob | A | 14550 | 14550 | 10 июн 2022 г. |
| Holmen Bob | A | 21132 | 4466 | 10 июн 2022 г. |
| Broder Samuel | A | 14550 | 14550 | 10 июн 2022 г. |
| Broder Samuel | A | 4466 | 4466 | 10 июн 2022 г. |
| Humer Kristian | A | 14550 | 14550 | 10 июн 2022 г. |
Новостная лента
Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference
GlobeNewsWire
02 ноя 2022 г. в 07:30
BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, President and Chief Executive Officer, will present at the 13th Annual Jefferies Global Healthcare Conference, being held in London, United Kingdom, on Thursday, November 17, 2022, at 7:25 a.m. GMT.
Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
GlobeNewsWire
05 окт 2022 г. в 08:05
BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced it will present two posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held in Boston, MA from November 8 - 12, 2022.
Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
GlobeNewsWire
21 сент 2022 г. в 16:05
BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced it will present additional preclinical data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held September 28 – October 1, 2022 at the New York Hilton Midtown in New York, New York.
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire
23 авг 2022 г. в 07:30
BOSTON, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today announced that Company management will participate in the following investor conferences in September 2022:
Best Penny Stocks To Buy? 3 To Watch With Insider Buying In February
PennyStocks
21 февр 2022 г. в 13:23
Insiders are scooping up these penny stocks in February. The post Best Penny Stocks To Buy?